ABT241227C114000
- 0.93
- -0.22-19.13%
Abbott Laboratories Newsroom
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Express News | Abbott Laboratories announced that it has reached an agreement with Medical Devices company DexCom to resolve all patent disputes between the two parties regarding continuous glucose monitoring devices.
Express News | DexCom and Abbott Laboratories have reached a settlement in the patent litigation.
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: Agreement Will Result in Dismissal of All Pending Cases in Courts, Patent Offices Worldwide - Website
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Abbott Laboratories' (NYSE:ABT) Investors Will Be Pleased With Their Respectable 43% Return Over the Last Five Years
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135
Unusual Options Activity: SLB, Z and Others Attract Market Bets, SLB V/OI Ratio Reaches 375.0
EST Dec 19th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Abbott Laboratories (ABT) Gets a Buy From Piper Sandler
This Is Why You Should Turn Defensive, Underweight Cyclicals – UBS
Least Shorted S&P 500 Stocks in November
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
Express News | Abbott : RBC Raises Target Price to $135 From $130
Express News | Abbott's Freestyle Libre® 2 Now Reimbursed for Children and Adults Living With Diabetes in Alberta
Bernstein Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $133